Search PubMed⌕ Search

Biomedical subjects

J Tsuchiya

Publications and source records attributed to J Tsuchiya.

At least 109 records · Page 6Linked to original sources
PubMed1982

First Japanese family with the unstable hemoglobin Zürich [beta 63(e7) His leads to Arg].

Abnormal hemoglobin, which was latter identified as hemoglobin Zürich, was discovered in a 45-year-old female with severe valvular heart disease, congestive heart failure and moderate anemia and hyperbilirubinemia. Same abnormal hemoglobin was demonstrated in her two apparently healthy sons. This is the first reported family of hemoglobin Zürich in Japan.

Adolescent↗
PubMed1982

[Clinical investigation of cefotiam against infections complicated by acute leukemia].

Clinical investigation of cefotiam and aminoglycosides combination use against infections complicated by acute leukemia was performed, and the results obtained were as follows. 1) Sixteen patients were treated with cefotiam in doses 4--6 grams per day parenterally. The clinical effectiveness were excellent 47.6%, good 14.3%, fair 9.5% and poor 28.6%. No significant differences in therapeutic efficacy was observed between the patients given CTM 4 g/day and CTM 6 g/day. 2) It was considered that the clinical effectiveness of CTM has not been influenced by the difference of a number of maturation granulocyte. CTM has showed a certain, though not distinctive, efficacy compared with CFX. 3) As side effects with CTM, eruption appeared in 1 case, and no remarkable laboratory findings was observed. Cefotiam is thus considered to be a useful drug for the treatment of infections complicated by acute leukemia.

Acute Disease↗
PubMed1982

[Current status of treatment for multiple myeloma].

The current status of treatment for multiple myeloma was reviewed. Recently, the response rate and survival for patients with multiple myeloma have improved with an introduction of combination chemotherapy. The addition of prednisolone to the regimen including alkylating agents clearly improved a response rate by 20% and extended survival by approximately 5 months. More recently, the use of multiple-drug combinations, such as VMCP and VMCBP schedules, seems to yield the best response rate. However, current improvements in survival of myeloma patients cannot be attributed fully to improved chemotherapy on the basis of the findings that the annual incidence and the number of patients with low tumor burden increase progressively, and the patients in the early stage of the disease have a high value for the incidence of long survival. Furthermore, earlier diagnosis, a low frequency of severe renal failure, and superior control of infections may likely influence the duration of survival. In order to cure the malignant tumor disease, it is necessary to eradicate every viable tumor cell in the host. Unfortunately, the most recently utilized combination chemotherapy has shown little evidence of permanent cure of multiple myeloma, even in patients with low tumor burden, i.e., effective treatment with currently available agents causes only an initial 1-2 log fall in the total body myeloma cell mass and an additional treatment does not reduce the residual tumor cell mass. Therefore, further studies of new drugs with major activity against plasma cell myeloma are expected.

Antineoplastic Agents↗
PubMed1981

[Acute toxicity of ketoprofen intrarectally administered in rats, with special reference to histopathological changes (author's transl)].

Acute toxicity was studied on Ketoprofen, one of the non-steroidal antiinflammatory analgesics, using SPF rats. Ketoprofen was intrarectally administered in three forms such as pure powder (KP), KP suspension in CMC solution (KP-CMC) and a mixture of KP with powdered basic materials of capsule (KP-T10). The results obtained were as follows:1. LD50 values of terms of KP were 84 mg/kg in male rats and 122 mg/kg in female rats when KP-CMC was administered intrarectally, and 117 mg/kg in male and 92 mg/kg in female when KP-T10 was administered intrarectally., while peroral administration of KP-CMC showed LD50 values of 68 mg/kg in males and 78 mg/kg in females in terms of KP. 2. Major toxic signs of KP were ulceration on small intestines and peritonitis. Degeneration of hepathocytes and decrease in thymus lymphocytes were also observed. 3. Minimum lethal dose of KP-T10 was slightly higher than that of KP-CMC.

Administration, Oral↗
PubMed1981

[Toxicological study on the anorectal irritation and systemic organ toxicity evoked by long-term intrarectal administration of ketoprofen in rabbits (author's transl)].

Ketoprofen (KP) was administered intrarectally and perorally to rabbits weighing approximately 3 kg of both sexes for a period of 13 weeks, in order to study the anorectal irritation and chronic systemic organ toxicity of KP which was capsulated with the soft T10 capsule for rectal administration and with a hard capsule for peroral administration. Doses of capsulated drugs for one animal were 9.0 mg and 4.5 mg in terms of KP. All animals treated by these dose levels survived without showing any abnormal symptoms. Intrarectal administration of KP-T10 did not produce any mucosal lesions in digestive tracts, while peroral administration of KP with hard capsule induced ulcers in cecum or anus, and congestion in small intestines in a small number of cases. No pathological change was recognized in organs except for digestive tracts in all cases by autopsy. From the above results, it can be seen that the suppository of KP capsulated by the soft T10 does not show any irritating effect on anorectal mucosa and has no toxic effect on all organs systemically. Then, a suppository of KP-T10 can be used more harmlessly than the peroral capsulated KP.

Anal Canal↗